Molika Ashford

Our site uses cookies and related technologies, as described in our privacy policy, for purposes that may include site operation, analytics, enhanced user experience, or advertising. You may choose to consent to our use of these technologies or manage your own preferences.

NEW YORK – Shares of Exact Sciences were down around 25 percent on Wednesday morning after the company said on Tuesday evening after the close of

Premium Save for later NEW YORK – Molecular diagnostics firm Veracyte said this week that it is encouraged by recently reported data from a study that confirmed the performance of its core Decipher prostate cancer test across different ancestries, specifically in African American men.

NEW YORK – Researchers at St. Jude Children's Research Hospital have developed a non-invasive comprehensive genomic profiling assay designed

NEW YORK – Lab leaders have been noting a growing embrace of comprehensive sequencing tests to aid the diagnosis and care of hematologic cancer patients.

NEW YORK – Researchers led by a team at McGill University have developed a sequencing-based assay for the early detection of gynecologic cancers, which they are currently validating in a prospective study.

Premium Save for later NEW YORK – New data highlighted this week at the San Antonio Breast Cancer Symposium has added evidence supporting the value of using polygenic risk scores (PRS) in assessing women's risk of developing breast cancer and confirmed that, when used in the clinic, PRS tests do lead to changes in patient screening. PRS scores also, according to data presented at the meeting, can refine cancer risk in individuals with benign breast disease.

NEW YORK – Researchers stopped a Phase III trial testing GlaxoSmithKline's PARP inhibitor Zejula (niraparib) as an adjuvant treatment of early-stage

NEW YORK – Guardant Health and ClearNote Health announced this week that their liquid biopsy assays have passed an assessment by the National Cancer

Premium Save for later NEW YORK – Investigators from the ongoing TRACERx trial published a new report this week highlighting findings from a subset of patients tested using Personalis' molecular/minimal residual disease (MRD) test, dubbed NeXT Personal, which is designed to catch DNA fragments shed from a cancerous tumor into a patient's blood.